{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glargine+insulin+vs+regular+insulin",
    "query": {
      "intervention": "Glargine insulin vs regular insulin"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 32,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glargine+insulin+vs+regular+insulin&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T04:08:03.000Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00348374",
      "title": "Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Insulin Lispro",
          "type": "DRUG"
        },
        {
          "name": "Exubera",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 191,
      "start_date": "2006-06",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2010-03-16",
      "last_synced_at": "2026-09-30T04:08:03.000Z",
      "location_count": 62,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Malvern",
          "state": "Arkansas"
        },
        {
          "city": "Foot Hill Ranch",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00348374"
    },
    {
      "nct_id": "NCT02843399",
      "title": "Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus Type 2"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 15498,
      "start_date": "2016-08-15",
      "completion_date": "2016-12-15",
      "has_results": false,
      "last_update_posted_date": "2017-12-15",
      "last_synced_at": "2026-09-30T04:08:03.000Z",
      "location_count": 1,
      "location_summary": "Wilmington, Delaware",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02843399"
    },
    {
      "nct_id": "NCT00046462",
      "title": "Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Lantus (insulin glargine [rDNA origin] injection)",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Glyburide",
          "type": "DRUG"
        },
        {
          "name": "Thiazolidinedione",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 240,
      "start_date": "2001-11",
      "completion_date": "2004-12",
      "has_results": false,
      "last_update_posted_date": "2011-01-11",
      "last_synced_at": "2026-09-30T04:08:03.000Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00046462"
    },
    {
      "nct_id": "NCT01107717",
      "title": "Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "metformin\\pioglitazone\\exenatide",
          "type": "DRUG"
        },
        {
          "name": "metformin, glyburide and glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 318,
      "start_date": "2009-01",
      "completion_date": "2023-02-03",
      "has_results": true,
      "last_update_posted_date": "2024-09-05",
      "last_synced_at": "2026-09-30T04:08:03.000Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01107717"
    },
    {
      "nct_id": "NCT00222521",
      "title": "Insulin Glargine Vs Standard Insulin Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis Related Diabetes"
      ],
      "interventions": [
        {
          "name": "Glargine insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2003-04",
      "completion_date": "2005-08",
      "has_results": false,
      "last_update_posted_date": "2005-09-22",
      "last_synced_at": "2026-09-30T04:08:03.000Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00222521"
    },
    {
      "nct_id": "NCT04157738",
      "title": "A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus",
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Rapid-Acting Insulin",
          "type": "DRUG"
        },
        {
          "name": "Long acting insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "15 Years",
        "sex": "ALL",
        "summary": "7 Years to 15 Years"
      },
      "enrollment_count": 24,
      "start_date": "2019-11-27",
      "completion_date": "2020-12-17",
      "has_results": true,
      "last_update_posted_date": "2021-09-30",
      "last_synced_at": "2026-09-30T04:08:03.000Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04157738"
    },
    {
      "nct_id": "NCT00551538",
      "title": "24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Lispro mix 75/25",
          "type": "DRUG"
        },
        {
          "name": "Glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 15,
      "start_date": "2003-05",
      "completion_date": "2004-12",
      "has_results": false,
      "last_update_posted_date": "2010-10-13",
      "last_synced_at": "2026-09-30T04:08:03.000Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00551538"
    },
    {
      "nct_id": "NCT01226043",
      "title": "Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Insulin Glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 405,
      "start_date": "2010-10",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2013-08-12",
      "last_synced_at": "2026-09-30T04:08:03.000Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01226043"
    },
    {
      "nct_id": "NCT00402909",
      "title": "Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Nateglinide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "78 Years",
        "sex": "ALL",
        "summary": "18 Years to 78 Years"
      },
      "enrollment_count": 28,
      "start_date": "2006-11",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2017-02-24",
      "last_synced_at": "2026-09-30T04:08:03.000Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00402909"
    },
    {
      "nct_id": "NCT04460326",
      "title": "Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Treated With Insulin"
      ],
      "interventions": [
        {
          "name": "Insulin glargine",
          "type": "DRUG"
        },
        {
          "name": "NovoLog",
          "type": "DRUG"
        },
        {
          "name": "Insulin Fiasp",
          "type": "DRUG"
        },
        {
          "name": "Standard carbohydrate diet",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Boston Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 137,
      "start_date": "2020-12-07",
      "completion_date": "2023-05-27",
      "has_results": true,
      "last_update_posted_date": "2024-03-19",
      "last_synced_at": "2026-09-30T04:08:03.000Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04460326"
    }
  ]
}